260 terminated. 260 Phase 2, 65 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 260 | Terminated 260 |
| Phase 1 | 65 | Terminated 65 |
| Phase 3 | 3 | Terminated 3 |
Follow Urologic Neoplasms: new trials by email Literature Review of Urologic Neoplasms trials Research Report on Urologic Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Intervention of Bladder Cancer by CAR-T 4SCAR-PSMA, 4SCAR-FRa - Bladder Cancer, Urothelial Carcinoma Bladder | Phase 1 / Phase 2 | Terminated | Shenzhen Geno-Immune Medical Institute | 20 | 2025-08-01 | 2026-10-30 |
| Efficacy and Safety of Finerenone and Empagliflozin in Delaying Renal Function Progression After Radical Nephrectomy in High-Risk CKD Patients: A Multicenter RCT Finerenone (BAY 94-8862), Empagliflozin 10 mg - Renal Cell Carcinoma (Kidney Cancer), Renal Cell Carcinoma (RCC) | Phase 2 | Terminated | Jinling Hospital, China | 10 | 2025-01-01 | 2025-12-11 |
| A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AUR 109 in Patients With Colorectal, Ovarian, and Renal Cancers AUR109 200mg, AUR109 300mg, AUR109 400mg - Ovarian Cancer, Colorectal Cancer | Phase 2 | Terminated | Aurigene Discovery Technologies Limited | 29 | 2024-11-09 | 2026-04-17 |
| A Clinical Gene Therapy Study With Hematopoietic Stem Cells for the Treatment, With Single Dose of Temferon, of Patients Suffering From Metastatic Renal Cell Carcinoma Temferon, Pembrolizumab, Cabozantinib - Clear Cell RCC | Phase 1 / Phase 2 | Terminated | Genenta Science | 10 | 2024-10-22 | 2026-02-09 |
| A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive INCB099280 - Advanced Solid Tumor | Phase 2 | Terminated | Incyte Corporation | 73 | 2023-10-30 | 2026-10-20 |
| Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc) NKT2152, palbociclib, sasanlimab - ccRCC, Clear Cell Renal Cell Carcinoma | Phase 2 | Terminated | NiKang Therapeutics, Inc. | 18 | 2023-07-28 | 2025-11-12 |
| Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC IMSA101, Immune checkpoint inhibitor, PULSAR - Oligometastatic Disease | Phase 2 | Terminated | ImmuneSensor Therapeutics Inc. | 6 | 2023-06-28 | 2025-10-20 |
| Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer Lymphadenectomy, Radical Cystectomy, Sacituzumab Govitecan - Muscle Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8 | Phase 2 | Terminated | University of Washington | 4 | 2023-06-15 | 2026-04-27 |
| 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors 89Zr-girentuximab for PET/CT imaging of CAIX positive tumors - Cervical Cancer, Colorectal Cancer | Phase 2 | Terminated | Telix Pharmaceuticals (Innovations) Pty Ltd | 11 | 2023-06-06 | 2025-07-10 |
| A Study of OMX-0407 in Patients With Previously Treated Solid Tumours That Can't be Removed Surgically OMX-0407 - Solid Tumor | Phase 1 / Phase 2 | Terminated | iOmx Therapeutics AG | 68 | 2023-03-30 | 2026-07-24 |
| Trial of PRO1160 (GEN1160) in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (PRO1160-001) GEN1160 - Renal Cell Carcinoma, Nasopharyngeal Carcinoma | Phase 1 / Phase 2 | Terminated | Genmab | 42 | 2023-03-15 | 2026-03-04 |
| NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours Fosifloxuridine Nafalbenamide, Leucovorin, Pembrolizumab - Advanced Cancer, Advanced Solid Tumor | Phase 1 / Phase 2 | Terminated | NuCana plc | 19 | 2023-03-08 | 2026-07-23 |
| CD8 Minibody Repeatability Study Zirconium 89Zr crefmirlimab berdoxam - Melanoma, Renal Cell Carcinoma | Phase 2 | Terminated | ImaginAb, Inc. | 3 | 2023-02-16 | 2024-12-03 |
| Perioperative TORIPALIMAB Plus LENVATINIB in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PLUTO) Toripalimab, Lenvatinib - Renal Cell Carcinoma (RCC) | Phase 2 | Terminated | Jinling Hospital, China | 17 | 2022-12-20 | 2026-03-05 |
| Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial Cancer Biospecimen Collection, Bone Scan, Computed Tomography - Metastatic Urothelial Carcinoma, Platinum-Resistant Urothelial Carcinoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 1 | 2022-11-22 | 2025-08-17 |
| Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy (SWOG GAP TRIAL) Therapeutic Conventional Surgery, Avelumab, Gemcitabine Hydrochloride - Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall, Infiltrating Renal Pelvis and Ureter Urothelial Carcinoma | Phase 2 | Terminated | SWOG Cancer Research Network | 6 | 2022-08-10 | 2024-12-30 |
| A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours AZD8853, Zirconium-89 crefmirlimab berdoxam - Urinary Bladder Neoplasms, Colorectal Cancer | Phase 1 / Phase 2 | Terminated | AstraZeneca | 17 | 2022-06-07 | 2024-10-01 |
| Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer Nivolumab, Quality-of-Life Assessment, Questionnaire Administration - Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma | Phase 2 | Terminated | M.D. Anderson Cancer Center | 15 | 2022-05-03 | 2026-03-20 |
| A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours [225Ac]-FPI-1966, [111In]-FPI-1967, vofatamab - Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma | Phase 1 / Phase 2 | Terminated | Fusion Pharmaceuticals Inc. | 6 | 2022-04-20 | 2023-12-19 |
| A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors TAK-500, Pembrolizumab, Tocilizumab - Pancreatic Cancer, Hepatocellular Cancer | Phase 1 / Phase 2 | Terminated | Takeda | 61 | 2022-04-14 | 2026-01-22 |
Showing 20 of 260. Sign in to see all of them.
Carcinoma, Renal Cell (145) · Urinary Bladder Neoplasms (92) · Kidney Neoplasms (61) · Neoplasm Metastasis (36) · Melanoma (32) · Carcinoma, Non-Small-Cell Lung (28) · Neoplasms (25) · Carcinoma, Transitional Cell (24) · Colorectal Neoplasms (16) · Ovarian Neoplasms (16) · Breast Neoplasms (13) · Pancreatic Neoplasms (12) · Sarcoma (12) · Esophageal Neoplasms (11) · Triple Negative Breast Neoplasms (11)
Female Urogenital Diseases (260) · Female Urogenital Diseases and Pregnancy Complications (260) · Male Urogenital Diseases (260) · Urogenital Diseases (260) · Urogenital Neoplasms (258) · Neoplasms by Site (257) · Urologic Diseases (257) · Neoplasms (235) · Neoplasms by Histologic Type (192) · Neoplasms, Glandular and Epithelial (182) · Carcinoma (174) · Kidney Diseases (167) · Adenocarcinoma (147) · Kidney Neoplasms (108)
Gemcitabine (25) · Nivolumab (22) · Sunitinib (19) · pembrolizumab (18) · Cisplatin (14) · Everolimus (14) · Sorafenib (14) · Bevacizumab (11) · Interleukin-2 (11) · avelumab (10) · aldesleukin (8) · Cyclophosphamide (7) · atezolizumab (7) · Axitinib (6) · Carboplatin (6)
National Cancer Institute (NCI) (26) · M.D. Anderson Cancer Center (10) · Hoffmann-La Roche (4) · Medical University of South Carolina (4) · Memorial Sloan Kettering Cancer Center (4) · University of Michigan Rogel Cancer Center (4) · Genmab (3) · Novartis Pharmaceuticals (3) · Pfizer (3) · SWOG Cancer Research Network (3) · University of Chicago (3) · University of Wisconsin, Madison (3) · Agenus Inc. (2) · Association of Urologic Oncology (AUO) (2) · Bayer (2)
United States (193) · France (21) · United Kingdom (20) · Italy (19) · Spain (19) · Canada (17) · Germany (13) · South Korea (12) · Australia (9) · Netherlands (9) · Taiwan (9) · China (8) · Hungary (7) · Poland (6) · Belgium (5)
Gustavo Leone (4) · Steven A Rosenberg, M.D. (4) · Uzair B. Chaudhary, MD (3) · David S Schrump, M.D. (2) · Dean Bajorin, MD (2) · Dr. Sandy Srinivas (2) · Eric Jonasch (2) · Ramaprasad Srinivasan, M.D. (2)
PMID 18568488, PMID 19179301, PMID 20857170, PMID 21403127, PMID 21431345, PMID 22105611, PMID 22430088, PMID 23377668, PMID 23861247, PMID 24249435, PMID 24318901, PMID 24914044, PMID 25052451, PMID 25432172, PMID 25688511, PMID 25777345, PMID 26370220, PMID 26830617, PMID 27286790, PMID 28546463, PMID 30190302, PMID 30374686, PMID 31231785, PMID 31654285, PMID 32508818, PMID 32620210, PMID 32654362, PMID 33058158, PMID 33305087, PMID 33507454, PMID 33775123, PMID 33883177, PMID 34030643, PMID 34051177, PMID 35438782, PMID 35444059, PMID 36041086, PMID 36302175, PMID 36803840, PMID 37141847, PMID 37369081, PMID 37651261, PMID 37758574, PMID 38215355, PMID 38740030, PMID 38865671, PMID 39187984, PMID 39209782, PMID 39462179, PMID 40212021
2017 (8), 2016 (3), P30CA016672 (3), P30CA072720 (3), U10CA032102 (3), 2009 (2), 2014 (2), 2015 (2), 2018 (2), N01CM62202 (2), P30CA014520 (2), P30CA014599 (2), 2005 (1), 2008 (1), 2019 (1)